Shanghai Selling General Administrative from 2010 to 2025

601607 Stock   20.15  0.32  1.61%   
Shanghai Pharmaceuticals' Selling General Administrative is increasing over the years with slightly volatile fluctuation. Selling General Administrative is expected to dwindle to about 6.7 B. From 2010 to 2025 Shanghai Pharmaceuticals Selling General Administrative quarterly data regression line had arithmetic mean of  9,541,944,368 and r-squared of  0.49. View All Fundamentals
 
Selling General Administrative  
First Reported
2002-03-31
Previous Quarter
342 M
Current Value
8.6 B
Quarterly Volatility
1.9 B
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Shanghai Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Shanghai Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 2 B, Selling General Administrative of 6.7 B or Total Revenue of 314.3 B, as well as many indicators such as . Shanghai financial statements analysis is a perfect complement when working with Shanghai Pharmaceuticals Valuation or Volatility modules.
  
This module can also supplement various Shanghai Pharmaceuticals Technical models . Check out the analysis of Shanghai Pharmaceuticals Correlation against competitors.

Currently Active Assets on Macroaxis

Other Information on Investing in Shanghai Stock

Shanghai Pharmaceuticals financial ratios help investors to determine whether Shanghai Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Shanghai with respect to the benefits of owning Shanghai Pharmaceuticals security.